World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
72
Citations
24353
World Ranking
2180
National Ranking
82

Overview

Michele W. L. Teng is affiliated with the QIMR Berghofer Medical Research Institute in Australia. Their research primarily focuses on immunology, oncology, and related molecular and physiological studies.

Their work spans multiple key topics, including:

  • Immune Cell Function and Interaction
  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • T-cell and B-cell Immunology
  • CAR-T cell therapy research
  • HIV Research and Treatment
  • Adenosine and Purinergic Signaling

The main fields of study in their publications cover:

  • Immunology and Microbiology
  • Medicine

Subfields within their research include:

  • Immunology
  • Oncology
  • Molecular Biology
  • Virology
  • Physiology

Their recent papers illustrate a focus on immune mechanisms and cancer immunotherapy. These include:

  • The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation, 2020, Nature Immunology
  • Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma, 2020, Clinical Cancer Research
  • Control of Metastases via Myeloid CD39 and NK Cell Effector Function, 2020, Cancer Immunology Research
  • ROCK2 inhibition attenuates profibrogenic immune cell function to reverse thioacetamide-induced liver fibrosis, 2021, JHEP Reports
  • Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors, 2022, Science Translational Medicine

The scientist frequently publishes in the following venues:

  • Nature Immunology
  • Clinical Cancer Research
  • Cancer Immunology Research
  • JHEP Reports
  • Science Translational Medicine

Among their frequent collaborators are:

  • Mark J. Smyth
  • Kyohei Nakamura
  • Susanna S. Ng
  • Juming Yan
  • Xian-Yang Li

Best Publications

  • Cancer immunoediting and resistance to T cell-based immunotherapy

    Jake S. O’Donnell;Jake S. O’Donnell;Michele W. L. Teng;Michele W. L. Teng;Mark J. Smyth;Mark J. Smyth

  • Classifying Cancers Based on T-cell Infiltration and PD-L1

    Michele W.L. Teng;Michele W.L. Teng;Shin Foong Ngiow;Antoni Ribas;Mark J. Smyth;Mark J. Smyth

  • Translational biology of osteosarcoma

    Maya Kansara;Michele W. Teng;Mark J. Smyth;David M. Thomas

  • Combination cancer immunotherapies tailored to the tumour microenvironment.

    Mark J. Smyth;Shin Foong Ngiow;Antoni Ribas;Michele W. L. Teng

  • IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases

    Michele W L Teng;Edward P Bowman;Joshua J McElwee;Mark J Smyth

  • Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease

    Jing Liu;Jing Liu;Stephen J. Blake;Michelle C.R. Yong;Heidi Harjunpää;Heidi Harjunpää

  • Targeting immunosuppressive adenosine in cancer

    Dipti Vijayan;Arabella Young;Michele W.L. Teng;Mark J. Smyth

  • De-novo and acquired resistance to immune checkpoint targeting

    Nicholas L Syn;Michele W L Teng;Tony S K Mok;Ross A Soo

  • Anti-TIM3 Antibody Promotes T Cell IFN-γ–Mediated Antitumor Immunity and Suppresses Established Tumors

    Shin Foong Ngiow;Bianca von Scheidt;Hisaya Akiba;Hideo Yagita

  • Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells

    Yulong Gao;Yulong Gao;Fernando Souza-Fonseca-Guimaraes;Fernando Souza-Fonseca-Guimaraes;Fernando Souza-Fonseca-Guimaraes;Tobias Bald;Susanna S Ng;Susanna S Ng

  • CD4+CD25+ T Regulatory Cells Suppress NK Cell-Mediated Immunotherapy of Cancer

    Mark J. Smyth;Michele W. L. Teng;Jeremy Swann;Konstantinos Kyparissoudis

  • Resistance to PD1/PDL1 checkpoint inhibition.

    Jake S. O'Donnell;Georgina V. Long;Richard A. Scolyer;Michele W.L. Teng

  • TIGIT predominantly regulates the immune response via regulatory T cells

    Sema Kurtulus;Kaori Sakuishi;Shin-Foong Ngiow;Shin-Foong Ngiow;Nicole Joller;Nicole Joller

  • Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.

    John Stagg;Sherene Loi;Upulie Divisekera;Shin Foong Ngiow

  • Immune-mediated dormancy: an equilibrium with cancer

    Michele W. L. Teng;Jeremy B. Swann;Catherine M. Koebel;Robert D. Schreiber

  • CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis

    John Stagg;Upulie Divisekera;Helene Duret;Tim Sparwasser

  • Cancer immunoediting by the innate immune system in the absence of adaptive immunity

    Timothy O’Sullivan;Robert Saddawi-Konefka;William Vermi;Catherine M. Koebel

  • Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses

    Arabella Young;Arabella Young;Shin Foong Ngiow;Shin Foong Ngiow;Deborah S. Barkauskas;Erin Sult

  • PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux.

    Jake S. O’Donnell;Daniela Massi;Michele W.L. Teng;Mario Mandala

  • From mice to humans: developments in cancer immunoediting

    Michele W.L. Teng;Jerome Galon;Wolf-Herman Fridman;Mark J. Smyth

Frequent Co-Authors

Mark J. Smyth
Mark J. Smyth QIMR Berghofer Medical Research Institute
Phillip K. Darcy
Phillip K. Darcy Peter MacCallum Cancer Centre
Michael H. Kershaw
Michael H. Kershaw Peter MacCallum Cancer Centre
Shin Foong Ngiow
Shin Foong Ngiow University of Pennsylvania
Geoffrey R. Hill
Geoffrey R. Hill Fred Hutchinson Cancer Research Center
Kazuyoshi Takeda
Kazuyoshi Takeda Juntendo University
Joseph A. Trapani
Joseph A. Trapani Peter MacCallum Cancer Centre
Stephen M. Jane
Stephen M. Jane Monash University
Hideo Yagita
Hideo Yagita Juntendo University
Richard A. Scolyer
Richard A. Scolyer Royal Prince Alfred Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in studying Immunology in the USA, exploring related healthcare degrees can open diverse career pathways. One popular option is becoming a Licensed Practical Nurse (LPN). If you're concerned about admission difficulty, consider looking into which lpn programs are easiest to get into to find accessible programs that offer a solid foundation in healthcare.

Nurses aiming to advance their careers might explore nurse practitioner degrees. Some programs are designed for smooth transitions, highlighted in guides like easiest nurse practitioner program, which can help streamline your path toward advanced practice roles.

For a more specialized focus, particularly in mental health, Psychiatric-Mental Health Nurse Practitioner (PMHNP) programs provide critical training. When choosing an online program, it's essential to consider clinical placement success. Detailed lists of top online pmhnp programs with best clinical placement rates can guide your decision.

Cost is also a factor for many students. If budget constraints are a concern, exploring the cheapest online pmhnp programs is a practical approach to balancing quality education with affordability.

Best Scientists Citing Michele W. L. Teng

Trending Scientists